Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.56 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | PPOX | P50336 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19563652 | 0.86 | HTR2A (0.51) | HTR2ASLC6A4KCNH2EPAS1FFAR1 | |
| SCHEMBL11124773 | 0.83 | MEN1 (0.54) | HTR2ASLC6A4KCNH2EPAS1FFAR1 | |
| SCHEMBL18570871 | 0.83 | SCN8A (0.50) | HTR2ASLC6A4KCNH2FFAR1MEN1 | |
| SCHEMBL18570579 | 0.81 | L3MBTL1 (0.46) | HTR2ASLC6A4KCNH2EPAS1FFAR1 | |
| SCHEMBL4939724 | 0.81 | HTR2A (0.53) | HTR2ASLC6A4KCNH2EPAS1KMT2A | |
| SCHEMBL22809589 | 0.80 | SLC6A4 (0.56) | HTR2ASLC6A4KCNH2FFAR1KMT2A | |
| SCHEMBL18570517 | 0.80 | L3MBTL1 (0.62) | HTR2ASLC6A4KCNH2L3MBTL1RAB9A | |
| SCHEMBL19563647 | 0.80 | SCN8A (0.46) | HTR2ASLC6A4KCNH2FFAR1KMT2A | |
| SCHEMBL276174 | 0.80 | EPAS1 (0.46) | HTR2ASLC6A4KCNH2EPAS1FFAR1 | |
| SCHEMBL7138558 | 0.80 | LMNA (0.57) | EPAS1FFAR1TTRKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084165-B2 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC (US) | 2006-08-01 | — | — | US | disclosed |
| US-20040048856-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-6677378-B2 | AS SEROTONIN, NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS, FOR THERAPY OF CENTRAL NERVOUS SYSTEM AND OTHER DISORDERS | PFIZER INC. | 2004-01-13 | — | — | US | disclosed |
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC. | 2002-10-03 | — | — | US | disclosed |
| EP-1154984-A1 | INHIBITORS FOR UPTAKE OF SEROTONINE, DOPAMINE OR NOREPINEPHRINE | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050380-A1 | MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A4, SLC6A3 | HTR2A 24/4885SLC6A4 2/4885KCNH2 1224/4885 |
| US-20040048856-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A3, SLC18A2 | HTR2A 14/4885SLC6A4 4/4885KCNH2 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.